
Gianluigi Forloni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/178997/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identifying the Common Genetic Basis of Antidepressant Response. Biological Psychiatry Global Open Science, 2022, 2, 115-126.	1.0	31
2	A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. European Neuropsychopharmacology, 2022, 55, 86-95.	0.3	19
3	Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts. International Clinical Psychopharmacology, 2022, 37, 38-45.	0.9	9
4	Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study. European Neuropsychopharmacology, 2022, 56, 100-111.	0.3	5
5	Polygenic risk scores for neuropsychiatric, inflammatory, and cardioâ€metabolic traits highlight possible genetic overlap with suicide attempt and treatmentâ€emergent suicidal ideation. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2022, 189, 74-85.	1.1	8
6	The development of ADAM10 endocytosis inhibitors for the treatment of Alzheimer's disease. Molecular Therapy, 2022, 30, 2474-2490.	3.7	15
7	Quantitative MRI Harmonization to Maximize Clinical Impact: The RIN–Neuroimaging Network. Frontiers in Neurology, 2022, 13, 855125.	1.1	16
8	Induced pluripotent stem cell-based organ-on-a-chip as personalized drug screening tools: A focus on neurodegenerative disorders. Journal of Tissue Engineering, 2022, 13, 204173142210953.	2.3	14
9	Preventive pharmacological treatment in subjects at risk for fatal familial insomnia: science and public engagement. Prion, 2022, 16, 66-77.	0.9	3
10	Peripheral inflammation exacerbates αâ€synuclein toxicity and neuropathology in Parkinson's models. Neuropathology and Applied Neurobiology, 2021, 47, 43-60.	1.8	53
11	Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110050.	2.5	21
12	Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimer's mice. Cell Death and Differentiation, 2021, 28, 203-218.	5.0	63
13	Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression. Journal of Affective Disorders, 2021, 279, 722-729.	2.0	7
14	Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 108, 110170.	2.5	36
15	Functionalized nanogel for treating activated astrocytes in spinal cord injury. Journal of Controlled Release, 2021, 330, 218-228.	4.8	25
16	Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight. Progress in Molecular Biology and Translational Science, 2021, 177, 175-202.	0.9	21
17	Defective cyclophilin A induces TDP-43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia. Brain, 2021, 144, 3710-3726.	3.7	13
18	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biological Psychiatry, 2021, 89, 825-835.	0.7	10

#	Article	IF	CITATIONS
19	Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease. Molecular Psychiatry, 2021, 26, 5797-5811.	4.1	30
20	Convergent and Discriminant Validity of Default Mode Network and Limbic Network Perfusion in Amnestic Mild Cognitive Impairment Patients. Journal of Alzheimer's Disease, 2021, 82, 1797-1808.	1.2	4
21	Plasmatic Hippuric Acid as a Hallmark of Frailty in an Italian Cohort: The Mediation Effect of Fruit–Vegetable Intake. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 2081-2089.	1.7	12
22	Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression. Current Medicinal Chemistry, 2021, 28, 4296-4320.	1.2	1
23	Hippuric acid: Could became a barometer for frailty and geriatric syndromes?. Ageing Research Reviews, 2021, 72, 101466.	5.0	30
24	Deletion of calcineurin from astrocytes reproduces proteome signature of Alzheimer's disease and epilepsy and predisposes to seizures. Cell Calcium, 2021, 100, 102480.	1.1	6
25	A Conformation Variant of p53 Combined with Machine Learning Identifies Alzheimer Disease in Preclinical and Prodromal Stages. Journal of Personalized Medicine, 2021, 11, 14.	1.1	19
26	Repositioning doxycycline for treating Parkinson's disease: Evidence from a preâ€clinical mouse model. Alzheimer's and Dementia, 2021, 17, e056160.	0.4	0
27	Smoking and the risk of dementia in the oldestâ€old: The Monzino 80â€plus study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
28	Alcohol consumption and the risk of dementia in the oldest old: The Monzino 80â€plus study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
29	Flavonoidâ€Derived Human Phenylâ€Î³â€Valerolactone Metabolites Selectively Detoxify Amyloidâ€Î² Oligomers and Prevent Memory Impairment in a Mouse Model of Alzheimer's Disease. Molecular Nutrition and Food Research, 2020, 64, e1900890.	1.5	24
30	Selective Modulation of A1 Astrocytes by Drug-Loaded Nano-Structured Gel in Spinal Cord Injury. ACS Nano, 2020, 14, 360-371.	7.3	94
31	Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntington's Disease. Molecular Neurobiology, 2020, 57, 1889-1903.	1.9	38
32	CSF cutoffs for MCI due to AD depend on APOEε4 carrier status. Neurobiology of Aging, 2020, 89, 55-62.	1.5	11
33	P.179 Polygenic risk scores for multiple psychiatric, inflammatory and cardio-metabolic traits highlight possible genetic overlap with suicide attempt. European Neuropsychopharmacology, 2020, 40, S105-S106.	0.3	0
34	Chronic BACE-1 Inhibitor Administration in TASTPM Mice (APP KM670/671NL and PSEN1 M146V Mutation): An EEG Study. International Journal of Molecular Sciences, 2020, 21, 9072.	1.8	1
35	Alzheimer's disease: from basic science to precision medicine approach. BMJ Neurology Open, 2020, 2, e000079.	0.7	19
36	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 12184.	1.6	4

#	Article	IF	CITATIONS
37	3D brain tissue physiological model with co-cultured primary neurons and glial cells in hydrogels. Journal of Tissue Engineering, 2020, 11, 204173142096398.	2.3	14
38	Ongoing electroencephalographic rhythms related to exploratory movements in transgenic TASTPM mice. Alzheimer's and Dementia, 2020, 16, e039729.	0.4	0
39	Peripheral inflammation influences αâ€synuclein toxicity and neuropathology in Parkinson's disease models. Alzheimer's and Dementia, 2020, 16, e043358.	0.4	2
40	Anemia and the risk of dementia in the oldestâ€old: The Monzino 80â€plus populationâ€based study. Alzheimer's and Dementia, 2020, 16, e044445.	0.4	0
41	Red cell distribution width (RDW) and the risk of dementia in the oldestâ€old: The Monzino 80â€plus populationâ€based study. Alzheimer's and Dementia, 2020, 16, e044453.	0.4	0
42	Lifetime brain structural trajectories in TAUPS2APP mouse model of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e045523.	0.4	0
43	Front Cover: Flavonoidâ€Derived Human Phenylâ€Î³â€Valerolactone Metabolites Selectively Detoxify Amyloidâ€Î² Oligomers and Prevent Memory Impairment in a Mouse Model of Alzheimer's Disease. Molecular Nutrition and Food Research, 2020, 64, 2070011.	1.5	1
44	A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. Translational Psychiatry, 2020, 10, 50.	2.4	33
45	COVID-19 mortality in Lombardy: the vulnerability of the oldest old and the resilience of male centenarians. Aging, 2020, 12, 15186-15195.	1.4	46
46	Ongoing Electroencephalographic Rhythms Related to Exploratory Movements in Transgenic TASTPM Mice. Journal of Alzheimer's Disease, 2020, 78, 291-308.	1.2	2
47	Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers. Journal of Alzheimer's Disease, 2019, 69, 3-14.	1.2	18
48	Longitudinal Molecular Magnetic Resonance Imaging of Endothelial Activation after Severe Traumatic Brain Injury. Journal of Clinical Medicine, 2019, 8, 1134.	1.0	5
49	Doxycycline for Alzheimer's Disease: Fighting β-Amyloid Oligomers and Neuroinflammation. Frontiers in Pharmacology, 2019, 10, 738.	1.6	58
50	Genetic variation across RNA metabolism and cell death gene networks is implicated in the semantic variant of primary progressive aphasia. Scientific Reports, 2019, 9, 10854.	1.6	9
51	miR-146a and miR-181a are involved in the progression of mild cognitive impairment to Alzheimer's disease. Neurobiology of Aging, 2019, 82, 102-109.	1.5	76
52	Hydrogel-based delivery of Tat-fused protein Hsp70 protects dopaminergic cells in vitro and in a mouse model of Parkinson's disease. NPG Asia Materials, 2019, 11, .	3.8	28
53	Biophysical and in Vivo Studies Identify a New Natural-Based Polyphenol, Counteracting Aβ Oligomerization in Vitro and Aβ Oligomer-Mediated Memory Impairment and Neuroinflammation in an Acute Mouse Model of Alzheimer's Disease. ACS Chemical Neuroscience, 2019, 10, 4462-4475.	1.7	23
54	Neuroinflammation and the Gut Microbiota: Possible Alternative Therapeutic Targets to Counteract Alzheimer's Disease?. Frontiers in Aging Neuroscience, 2019, 11, 284.	1.7	95

#	Article	IF	CITATIONS
55	M67 PSYCHIATRIC DISORDERS AND SLC6A4 GENE VARIANTS: POSSIBLE MODULATION OF ALCOHOL DEPENDENCE AND ALZHEIMER'S DISEASE. European Neuropsychopharmacology, 2019, 29, S202-S203.	0.3	0
56	Alzheimer's Disease and Neurotransmission Gene Variants: Focus on Their Effects on Psychiatric Comorbidities and Inflammatory Parameters. Neuropsychobiology, 2019, 78, 79-85.	0.9	9
57	Clinical trials of prion disease therapeutics. Current Opinion in Pharmacology, 2019, 44, 53-60.	1.7	21
58	Stem cell paracrine effect and delivery strategies for spinal cord injury regeneration. Journal of Controlled Release, 2019, 300, 141-153.	4.8	56
59	Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 69, 49-58.	1.2	8
60	Nanovector-Mediated Drug Delivery in Spinal Cord Injury: A Multitarget Approach. ACS Chemical Neuroscience, 2019, 10, 1173-1182.	1.7	20
61	Plasma Aβ42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. Journal of Alzheimer's Disease, 2019, 69, 37-48.	1.2	23
62	Corrected QT Interval Prolongation in Psychopharmacological Treatment and Its Modulation by Genetic Variation. Neuropsychobiology, 2019, 77, 67-72.	0.9	13
63	Cellular prion protein neither binds to alpha-synuclein oligomers nor mediates their detrimental effects. Brain, 2019, 142, 249-254.	3.7	38
64	Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. Journal of Alzheimer's Disease, 2019, 69, 15-35.	1.2	34
65	Plasma and Brain Concentrations of Doxycycline after Single and Repeated Doses in Wild-Type and APP23 Mice. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 32-40.	1.3	46
66	Review: PrP 106â€126 – 25 years after. Neuropathology and Applied Neurobiology, 2019, 45, 430-440.	1.8	19
67	Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. Nature Medicine, 2019, 25, 152-164.	15.2	111
68	Exploring Alzheimer's disease mouse brain through X-ray phase contrast tomography: From the cell to the organ. NeuroImage, 2019, 184, 490-495.	2.1	56
69	Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2. Brain, Behavior, and Immunity, 2018, 69, 591-602.	2.0	55
70	CXCR4 involvement in neurodegenerative diseases. Translational Psychiatry, 2018, 8, 73.	2.4	66
71	A Rational Structured Epitope Defines a Distinct Subclass of Toxic Amyloid-beta Oligomers. ACS Chemical Neuroscience, 2018, 9, 1591-1606.	1.7	21
72	Mesenchymal stem cells encapsulated into biomimetic hydrogel scaffold gradually release CCL2 chemokine in situ preserving cytoarchitecture and promoting functional recovery in spinal cord injury. Journal of Controlled Release, 2018, 278, 49-56.	4.8	80

#	Article	IF	CITATIONS
73	Novel targets in Alzheimer's disease: A special focus on microglia. Pharmacological Research, 2018, 130, 402-413.	3.1	46
74	Alzheimer's Disease, Oligomers, and Inflammation. Journal of Alzheimer's Disease, 2018, 62, 1261-1276.	1.2	141
75	Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 81, 203-210.	2.5	31
76	Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features. Journal of Molecular Neuroscience, 2018, 64, 62-74.	1.1	3
77	Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer's disease-like transgenic mouse model. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 609-618.	1.7	109
78	Single severe traumatic brain injury produces progressive pathology with ongoing contralateral white matter damage one year after injury. Experimental Neurology, 2018, 300, 167-178.	2.0	86
79	P2â€092: MRI ANALYSIS BY CHEMICAL EXCHANGE SATURATION TRANSFER SHOWS LOW CEREBRAL 2â€DEOXYâ€Dâ€GLUCOSE UPTAKE IN A MODEL OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P703.	0.4	0
80	Asymptomatic Carriers of Presenilin-1 E318G Variant Show no Cerebrospinal Fluid Biochemical Signs Suggestive of Alzheimer's disease in a Family with Late-onset Dementia. Current Alzheimer Research, 2018, 16, 1-7.	0.7	4
81	The serotonin transporter and the activity regulated cytoskeletonâ€associated protein genes in antidepressant response and resistance: <scp>5â€HTTLPR</scp> and other variants. Human Psychopharmacology, 2018, 33, e2682.	0.7	7
82	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	3.7	39
83	Exome sequencing in an Italian family with Alzheimer's disease points to a role for seizure-related gene 6 (SEZ6) rare variant R615H. Alzheimer's Research and Therapy, 2018, 10, 106.	3.0	15
84	Chemical exchange saturation transfer MRI shows low cerebral 2-deoxy-D-glucose uptake in a model of Alzheimer's Disease. Scientific Reports, 2018, 8, 9576.	1.6	33
85	Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models. Neurobiology of Aging, 2018, 70, 128-139.	1.5	52
86	Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. PLoS Medicine, 2018, 15, e1002487.	3.9	111
87	Ongoing Electroencephalographic Activity Associated with Cortical Arousal in Transgenic PDAPP Mice (hAPP V717F). Current Alzheimer Research, 2018, 15, 259-272.	0.7	8
88	Joint meeting: 54th Congress of the Italian Association of Neuropathology and Clinical Neurobiology (AINPeNC) / 44th Congress of the Italian Association for Cerebral Aging Research (AIRIC), Milan, Italy, May 17 – 19, 2018. , 2018, 37, 112-145.		1
89	Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 152-164.	0.9	107
90	Toll-like receptor 4-dependent glial cell activation mediates the impairment in memory establishment induced by β-amyloid oligomers in an acute mouse model of Alzheimer's disease. Brain, Behavior, and Immunity, 2017, 60, 188-197.	2.0	123

#	Article	IF	CITATIONS
91	Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 723-735.	1.8	21
92	Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI). Neurobiology of Aging, 2017, 53, 1-10.	1.5	59
93	Multifunctional liposomes delay phenotype progression and prevent memory impairment in a presymptomatic stage mouse model of Alzheimer disease. Journal of Controlled Release, 2017, 258, 121-129.	4.8	40
94	Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 482-490.	1.2	10
95	Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples. Advances in Therapy, 2017, 34, 1482-1497.	1.3	3
96	Applicability of [11 C]PIB micro-PET imaging for inÂvivo follow-up of anti-amyloid treatment effects in APP23 mouse model. Neurobiology of Aging, 2017, 57, 84-94.	1.5	17
97	Detection of prion seeding activity in the olfactory mucosa of patients with Fatal Familial Insomnia. Scientific Reports, 2017, 7, 46269.	1.6	41
98	Secretome released from hydrogel-embedded adipose mesenchymal stem cells protects against the Parkinson's disease related toxin 6-hydroxydopamine. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 121, 113-120.	2.0	50
99	Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS. Scientific Reports, 2017, 7, 8899.	1.6	30
100	Current Options for Cell Therapy in Spinal Cord Injury. Trends in Molecular Medicine, 2017, 23, 831-849.	3.5	141
101	Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's Aβ peptide. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 723-732.	1.7	47
102	On-going electroencephalographic rhythms related to cortical arousal in wild-type mice: the effect of aging. Neurobiology of Aging, 2017, 49, 20-30.	1.5	11
103	[P3–214]: ADFLAG [®] , A DIAGNOSTIC BLOOD TEST FOR PREâ€DEMENTIA STAGES OF ALZHEIMER' DISEASE. Alzheimer's and Dementia, 2017, 13, P1019.	^S 0.4	Ο
104	[P4–157]: CSF BIOMARKERS AND EFFECT OF APOLIPOPROTEIN E GENOTYPE, AGE AND SEX ON CUTâ€OFF DERIVATION IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1319.	0.4	4
105	[O2–15–05]: ALPHAâ€SYNUCLEIN OLIGOMERS INDUCE MEMORY IMPAIRMENT INFLUENCED BY RAPID GLIAL ACTIVATION. Alzheimer's and Dementia, 2017, 13, P595.	. SELL 8.4	0
106	The Anti-Prion Antibody 15B3 Detects Toxic Amyloid-β Oligomers. Journal of Alzheimer's Disease, 2016, 53, 1485-1497.	1.2	12
107	Frontotemporal Lobar Degeneration and MicroRNAs. Frontiers in Aging Neuroscience, 2016, 8, 17.	1.7	22
108	Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases. Movement Disorders, 2016, 31, 771-781.	2.2	88

7

#	Article	IF	CITATIONS
109	Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a â€~European <scp>ADNI</scp> study'. Journal of Internal Medicine, 2016, 279, 576-591.	2.7	64
110	CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2016, 52, 1203-1208.	1.2	18
111	P3â€189: Plasma Metabolic Alteration in MCI and Alzheimer's Disease Subjects. Alzheimer's and Dementia, 2016, 12, P894.	0.4	0
112	O5â€03â€05: Brain Sirtuinâ€2 Inhibition Improves Cognitive Performance and Affects Betaâ€Amyloid Processing in two Alzheimer's Disease Mouse Models. Alzheimer's and Dementia, 2016, 12, P384.	0.4	0
113	ECG alterations associated with psychotropic drug use in clinical settings: clinical and genetic predictors. European Neuropsychopharmacology, 2016, 26, S240-S241.	0.3	0
114	Role of neurodevelopment involved genes in psychiatric comorbidities and modulation of inflammatory processes in Alzheimer's disease. Journal of the Neurological Sciences, 2016, 370, 162-166.	0.3	12
115	Association between Sirtuin 1 Gene rs10997870 Polymorphism and Suicide Behaviors in Bipolar Disorder. Neuropsychobiology, 2016, 74, 1-7.	0.9	15
116	Differential transgene expression patterns in Alzheimer mouse models revealed by novel human amyloid precursor proteinâ€specific antibodies. Aging Cell, 2016, 15, 953-963.	3.0	22
117	Sirtuin 2 Inhibition Improves Cognitive Performance and Acts on Amyloid-β Protein Precursor Processing in Two Alzheimer's Disease Mouse Models. Journal of Alzheimer's Disease, 2016, 53, 1193-1207.	1.2	61
118	The role of single-nucleotide variants of the energy metabolism-linked genes <i>SIRT3</i> , <i>PPARGC1A</i> and <i>APOE</i> in amyotrophic lateral sclerosis risk. Genes and Genetic Systems, 2016, 91, 301-309.	0.2	10
119	Pulmonary administration of functionalized nanoparticles significantly reduces beta-amyloid in the brain of an Alzheimer's disease murine model. Nano Research, 2016, 9, 2190-2201.	5.8	13
120	Baseline CSF Aβ, Aβ/T-TAU and Aβ/P-tau distributions to classify pharmacog MCI patients. Neurobiology of Aging, 2016, 39, S30.	1.5	0
121	Loss of exosomes in progranulin-associated frontotemporal dementia. Neurobiology of Aging, 2016, 40, 41-49.	1.5	47
122	A new three dimensional biomimetic hydrogel to deliver factors secreted by human mesenchymal stem cells in spinal cord injury. Biomaterials, 2016, 75, 135-147.	5.7	141
123	Early modulation of pro-inflammatory microglia by minocycline loaded nanoparticles confers long lasting protection after spinal cord injury. Biomaterials, 2016, 75, 13-24.	5.7	110
124	SORL1 Gene is Associated with the Conversion from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 46, 771-776.	1.2	14
125	O2-14-05: Alpha-synuclein oligomers acutely induce memory deficits and brain inflammation. , 2015, 11, P209-P209.		0
126	Comparative Magnetic Resonance Imaging and Histopathological Correlates in Two SOD1 Transgenic Mouse Models of Amyotrophic Lateral Sclerosis. PLoS ONE, 2015, 10, e0132159.	1.1	23

#	Article	IF	CITATIONS
127	The Prevalence of Mild Cognitive Impairment in Diverse Geographical and Ethnocultural Regions: The COSMIC Collaboration. PLoS ONE, 2015, 10, e0142388.	1.1	225
128	Striatum and entorhinal cortex atrophy in AD mouse models: MRI comprehensive analysis. Neurobiology of Aging, 2015, 36, 776-788.	1.5	25
129	Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients. Journal of Neural Transmission, 2015, 122, 43-58.	1.4	14
130	Influence of socio-demographic features and apolipoprotein E epsilon 4 expression on the prevalence of dementia and cognitive impairment in a population of 70–74-year olds: The InveCe.Ab study. Archives of Gerontology and Geriatrics, 2015, 60, 334-343.	1.4	25
131	The Parkinson's Disease-Related Protein DJ-1 Protects Dopaminergic Neurons in vivo and Cultured Cells from Alpha-Synuclein and 6-Hydroxydopamine Toxicity. Neurodegenerative Diseases, 2015, 15, 13-23.	0.8	32
132	Transgenic Fatal Familial Insomnia Mice Indicate Prion Infectivity-Independent Mechanisms of Pathogenesis and Phenotypic Expression of Disease. PLoS Pathogens, 2015, 11, e1004796.	2.1	61
133	Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseases. Prion, 2015, 9, 75-79.	0.9	54
134	Neuronal cell adhesion genes and antidepressant response in three independent samples. Pharmacogenomics Journal, 2015, 15, 538-548.	0.9	34
135	The Continuing Failure of Bexarotene in Alzheimer's Disease Mice. Journal of Alzheimer's Disease, 2015, 46, 471-482.	1.2	28
136	On-Going Frontal Alpha Rhythms Are Dominant in Passive State and Desynchronize in Active State in Adult Gray Mouse Lemurs. PLoS ONE, 2015, 10, e0143719.	1.1	5
137	The SIRT1 promoter polymorphic site rs12778366 increases IL-6 related human mortality in the prospective study "Treviso Longeva (TRELONG)". International Journal of Molecular Epidemiology and Genetics, 2015, 6, 20-6.	0.4	4
138	Melatonin and the Charlson Comorbidity Index (CCI): The Treviso Longeva (Trelong) Study. International Journal of Biological Markers, 2014, 29, 253-260.	0.7	7
139	Environmental Enrichment Lessens Cognitive Decline in APP23 Mice Without Affecting Brain Sirtuin Expression. Journal of Alzheimer's Disease, 2014, 42, 851-864.	1.2	30
140	Multifunctional Liposomes Reduce Brain β-Amyloid Burden and Ameliorate Memory Impairment in Alzheimer's Disease Mouse Models. Journal of Neuroscience, 2014, 34, 14022-14031.	1.7	141
141	Stress Impairs Synaptic Plasticity in Triple-Transgenic Alzheimer's Disease Mice: Rescue by Ryanodine. Neurodegenerative Diseases, 2014, 13, 135-138.	0.8	15
142	Modulation of human longevity by SIRT3 single nucleotide polymorphisms in the prospective study "Treviso Longeva (TRELONG)― Age, 2014, 36, 469-478.	3.0	63
143	Synthesis and evaluation of a 18F-curcumin derivate for β-amyloid plaque imaging. Bioorganic and Medicinal Chemistry, 2014, 22, 2753-2762.	1.4	32
144	Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2014, 13, 150-158.	4.9	157

#	Article	IF	CITATIONS
145	In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [18F]flutemetamol. EJNMMI Research, 2014, 4, 37.	1.1	22
146	Nanovectorâ€mediated drug delivery for spinal cord injury treatment. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2014, 6, 506-515.	3.3	24
147	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	4.9	302
148	Polymeric nanoparticle system to target activated microglia/macrophages in spinal cord injury. Journal of Controlled Release, 2014, 174, 15-26.	4.8	100
149	P1-274: MAGNETIC RESONANCE IMAGING AND ALZHEIMER'S DISEASE: A LONGITUDINAL STUDY OF STRUCTURAL CHANGES IN DIFFERENT TRANSGENIC MODELS. , 2014, 10, P410-P410.		0
150	P1-278: METABOLIC ALTERATION IN ALZHEIMER'S DISEASE: A LONGITUDINAL STUDY WITH MAGNETIC RESONANCE SPECTROSCOPY IN DIFFERENT TRANSGENIC MODELS. , 2014, 10, P411-P411.		0
151	In Vivo Application of beta Amyloid Oligomers: A Simple Tool to Evaluate Mechanisms of Action and New Therapeutic Approaches. Current Pharmaceutical Design, 2014, 20, 2491-2505.	0.9	53
152	The neurodegeneration in Alzheimer disease and the prion protein. Prion, 2013, 7, 60-65.	0.9	12
153	Body mass index, lifestyles, physical performance and cognitive decline: The "Treviso Longeva (Trelong)―study. Journal of Nutrition, Health and Aging, 2013, 17, 378-384.	1.5	57
154	Association between Sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer's disease in two independent European samples. Journal of Neural Transmission, 2013, 120, 1709-1715.	1.4	30
155	A new paradigm for testing AD drugs – neuroimaging biomarkers as surrogate outcomes homologous in animals and humans. Drug Discovery Today: Therapeutic Strategies, 2013, 10, e63-e71.	0.5	0
156	Selective Nanovector Mediated Treatment of Activated Proinflammatory Microglia/Macrophages in Spinal Cord Injury. ACS Nano, 2013, 7, 9881-9895.	7.3	136
157	Brain aging and dementia during the transition from late adulthood to old age: design and methodology of the "Invece.Ab―population-based study. BMC Geriatrics, 2013, 13, 98.	1.1	39
158	Systematic Analysis of Injectable Materials and 3D Rapid Prototyped Magnetic Scaffolds: From CNS Applications to Soft and Hard Tissue Repair/Regeneration. Procedia Engineering, 2013, 59, 233-239.	1.2	60
159	Tunable hydrogel—Nanoparticles release system for sustained combination therapies in the spinal cord. Colloids and Surfaces B: Biointerfaces, 2013, 108, 169-177.	2.5	38
160	Current options for drug delivery to the spinal cord. Expert Opinion on Drug Delivery, 2013, 10, 385-396.	2.4	61
161	Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors. Neurobiology of Aging, 2013, 34, 1711.e7-1711.e13.	1.5	43
162	Effects of pharmacological agents, sleep deprivation, hypoxia and transcranial magnetic stimulation on electroencephalographic rhythms in rodents: Towards translational challenge models for drug discovery in Alzheimer's disease. Clinical Neurophysiology, 2013, 124, 437-451.	0.7	21

#	Article	IF	CITATIONS
163	The <i>SIRT2</i> polymorphism rs10410544 and risk of Alzheimer's disease in two Caucasian case–control cohorts. Alzheimer's and Dementia, 2013, 9, 392-399.	0.4	40
164	A New Face for Old Antibiotics: Tetracyclines in Treatment of Amyloidoses. Journal of Medicinal Chemistry, 2013, 56, 5987-6006.	2.9	76
165	Impact of 5-HTTLPR Polymorphism on Alexithymia in Alcoholic Patients After Detoxification Treatment. Journal of Addiction Medicine, 2013, 7, 372-373.	1.4	4
166	Longitudinal Amyloid Imaging in Mouse Brain with ¹¹ C-PIB: Comparison of APP23, Tg2576, and APP _{swe} -PS1 _{dE9} Mouse Models of Alzheimer Disease. Journal of Nuclear Medicine, 2013, 54, 1434-1441.	2.8	71
167	An N-terminal Fragment of the Prion Protein Binds to Amyloid-β Oligomers and Inhibits Their Neurotoxicity in Vivo. Journal of Biological Chemistry, 2013, 288, 7857-7866.	1.6	162
168	Development and Analysis of Semi-Interpenetrating Polymer Networks for Brain Injection in Neurodegenerative Disorders. International Journal of Artificial Organs, 2013, 36, 762-774.	0.7	10
169	C9ORF72 Hexanucleotide Repeat Number in Frontotemporal Lobar Degeneration: A Genotype-Phenotype Correlation Study. Journal of Alzheimer's Disease, 2013, 38, 799-808.	1.2	43
170	Hydrogel-Based Nanocomposites and Mesenchymal Stem Cells: A Promising Synergistic Strategy for Neurodegenerative Disorders Therapy. Scientific World Journal, The, 2013, 2013, 1-9.	0.8	25
171	Therapy in Prion Diseases. Current Topics in Medicinal Chemistry, 2013, 13, 2465-2476.	1.0	41
172	Effects of SORL1 Gene on Alzheimer's Disease. Focus on Gender, Neuropsychiatric Symptoms and Pro-Inflammatory Cytokines. Current Alzheimer Research, 2013, 10, 154-164.	0.7	12
173	Synergism Between Resveratrol and Crocin for Protection of Human Neuroblastoma SHSY-5Y Cells against Oxidative Stress. Planta Medica, 2013, 79, .	0.7	Ο
174	Association of SORL1 Alleles with Late-Onset Alzheimer's Disease. Findings from the GIGAS_LOAD Study and Mega-Analysis. Current Alzheimer Research, 2012, 9, 491-499.	0.7	13
175	Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurology, The, 2012, 11, 618-628.	4.9	319
176	Responsible nanotechnology development. Journal of Nanoparticle Research, 2012, 14, 1.	0.8	24
177	Body Mass Index, Cognition, Disability, APOE Genotype, and Mortality: The "Treviso Longeva―Study. American Journal of Geriatric Psychiatry, 2012, 20, 594-602.	0.6	23
178	Mutant PrP Suppresses Glutamatergic Neurotransmission in Cerebellar Granule Neurons by Impairing Membrane Delivery of VGCC α2δ-1 Subunit. Neuron, 2012, 74, 300-313.	3.8	64
179	Sustained Delivery of Chondroitinase ABC from Hydrogel System. Journal of Functional Biomaterials, 2012, 3, 199-208.	1.8	16
180	Neuroprotective Effects of Toll-Like Receptor 4 Antagonism in Spinal Cord Cultures and in a Mouse Model of Motor Neuron Degeneration. Molecular Medicine, 2012, 18, 971-981.	1.9	66

#	Article	IF	CITATIONS
181	Replication Study to Confirm the Role of CYP2D6 Polymorphism rs1080985 on Donepezil Efficacy in Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2012, 30, 745-749.	1.2	35
182	Interleukin-1α, interleukin-1β and tumor necrosis factor-α genetic variants and risk of dementia in the very old: evidence from the "Monzino 80-plus―prospective study. Age, 2012, 34, 519-526.	3.0	6
183	Multiple drug delivery hydrogel system for spinal cord injury repair strategies. Journal of Controlled Release, 2012, 159, 271-280.	4.8	84
184	Longitudinal Tracking of Human Fetal Cells Labeled with Super Paramagnetic Iron Oxide Nanoparticles in the Brain of Mice with Motor Neuron Disease. PLoS ONE, 2012, 7, e32326.	1.1	28
185	The Toxicity of a Mutant Prion Protein Is Cell-Autonomous, and Can Be Suppressed by Wild-Type Prion Protein on Adjacent Cells. PLoS ONE, 2012, 7, e33472.	1.1	13
186	Pyrroloquinoxaline hydrazones as fluorescent probes for amyloid fibrils. Organic and Biomolecular Chemistry, 2011, 9, 5137.	1.5	44
187	Hydrogels in Spinal Cord Injury Repair Strategies. ACS Chemical Neuroscience, 2011, 2, 336-345.	1.7	142
188	An APOE Haplotype Associated with Decreased Îμ4 Expression Increases the Risk of Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 235-245.	1.2	58
189	Insulin-like growth factor 1 receptor polymorphism rs2229765 and circulating interleukin-6 level affect male longevity in a population-based prospective study (Treviso Longevaâ^' TRELONG). Aging Male, 2011, 14, 257-264.	0.9	14
190	Macroautophagy and the proteasome are differently involved in the degradation of alpha-synuclein wild type and mutated A30P in an in vitro inducible model (PC12/TetOn). Neuroscience, 2011, 195, 128-137.	1.1	26
191	Tetracycline prevents AÎ ² oligomer toxicity through an atypical supramolecular interaction. Organic and Biomolecular Chemistry, 2011, 9, 463-472.	1.5	52
192	A Novel Study and Meta-Analysis of the Genetic Variation of the Serotonin Transporter Promoter in the Italian Population Do Not Support a Large Effect on Alzheimer's Disease Risk. International Journal of Alzheimer's Disease, 2011, 2011, 1-7.	1.1	5
193	Nanocomposites for Neurodegenerative Diseases: Hydrogel-Nanoparticle Combinations for a Challenging Drug Delivery. International Journal of Artificial Organs, 2011, 34, 1115-1127.	0.7	52
194	Differential effects of the isomers of fenfluramine and norfenfluramine on rat striatal acetylcholine content. Journal of Pharmacy and Pharmacology, 2011, 31, 706-706.	1.2	8
195	Comparison of the effects of the stereoisomers of fenfluramine on the acetylcholine content of rat striatum, hippocampus and nucleus accumbens. Journal of Pharmacy and Pharmacology, 2011, 32, 201-203.	1.2	16
196	The γ-Secretase Modulator CHF5074 Restores Memory and Hippocampal Synaptic Plasticity in Plaque-Free Tg2576 Mice. Journal of Alzheimer's Disease, 2011, 24, 799-816.	1.2	53
197	JNK Plays a Key Role in Tau Hyperphosphorylation in Alzheimer's Disease Models. Journal of Alzheimer's Disease, 2011, 26, 315-329.	1.2	108
198	Disease Tracking Markers for Alzheimer's Disease at the Prodromal (MCI) Stage. Journal of Alzheimer's Disease, 2011, 26, 159-199.	1.2	120

#	Article	IF	CITATIONS
199	Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 551-559.	1.7	149
200	In situ agar–carbomer hydrogel polycondensation: A chemical approach to regenerative medicine. Materials Letters, 2011, 65, 1688-1692.	1.3	21
201	APP Transgenic Mice: Their Use and Limitations. NeuroMolecular Medicine, 2011, 13, 117-137.	1.8	69
202	Rosuvastatin and Thapsigargin Modulate γ-Secretase Gene Expression and APP Processing in a Human Neuroglioma Model. Journal of Molecular Neuroscience, 2011, 43, 461-469.	1.1	6
203	Nephrin expression in adult rodent central nervous system and its interaction with glutamate receptors. Journal of Pathology, 2011, 225, 118-128.	2.1	30
204	Factors related to disability: Evidence from the "Treviso Longeva (TRELONG) Study― Archives of Gerontology and Geriatrics, 2011, 52, 309-316.	1.4	17
205	c-Jun N-terminal Kinase Regulates Soluble Aβ Oligomers and Cognitive Impairment in AD Mouse Model. Journal of Biological Chemistry, 2011, 286, 43871-43880.	1.6	74
206	β-amyloid oligomers and prion protein. Prion, 2011, 5, 10-15.	0.9	22
207	<i>TMEM106B</i> regulates progranulin levels and the penetrance of FTLD in <i>GRN</i> mutation carriers. Neurology, 2011, 76, 467-474.	1.5	211
208	Expression of Mutant or Cytosolic PrP in Transgenic Mice and Cells Is Not Associated with Endoplasmic Reticulum Stress or Proteasome Dysfunction. PLoS ONE, 2011, 6, e19339.	1.1	32
209	Vitamin B12 Levels in Alzheimer's Disease: Association with Clinical Features and Cytokine Production. Journal of Alzheimer's Disease, 2010, 19, 481-488.	1.2	39
210	Failure to Replicate an Association of rs5984894 SNP in the PCDH11X Gene in a Collection of 1,222 Alzheimer's Disease Affected Patients. Journal of Alzheimer's Disease, 2010, 21, 385-388.	1.2	11
211	Neuroprotective properties of resveratrol in different neurodegenerative disorders. BioFactors, 2010, 36, 370-376.	2.6	153
212	APOE epsilonâ€4 allele and cytokine production in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2010, 25, 338-344.	1.3	33
213	Role of Clycogen Synthase Kinase-3β in APP Hyperphosphorylation Induced by NMDA Stimulation in Cortical Neurons. Pharmaceuticals, 2010, 3, 42-58.	1.7	6
214	Cell Type-Specific Neuroprotective Activity of Untranslocated Prion Protein. PLoS ONE, 2010, 5, e13725.	1.1	26
215	Cognitive Deficits Associated with Alteration of Synaptic Metaplasticity Precede Plaque Deposition in AβPP23 Transgenic Mice. Journal of Alzheimer's Disease, 2010, 21, 1367-1381.	1.2	35
216	Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2295-2300.	3.3	435

#	Article	IF	CITATIONS
217	Blocking ADAM10 synaptic trafficking generates a model of sporadic Alzheimer's disease. Brain, 2010, 133, 3323-3335.	3.7	71
218	Worldwide distribution of <i>PSEN1</i> Met146Leu mutation. Neurology, 2010, 74, 798-806.	1.5	38
219	Sirtuins as Novel Targets for Alzheimer's Disease and Other Neurodegenerative Disorders: Experimental and Genetic Evidence. Journal of Alzheimer's Disease, 2010, 19, 11-26.	1.2	112
220	A New Fluorogenic Peptide Determines Proteasome Activity in Single Cells. Journal of Medicinal Chemistry, 2010, 53, 7452-7460.	2.9	20
221	The molecular genetics of sirtuins: association with human longevity and age-related diseases. International Journal of Molecular Epidemiology and Genetics, 2010, 1, 214-25.	0.4	22
222	APOE ε2 and ε4 influence the susceptibility for Alzheimer's disease but not other dementias. International Journal of Molecular Epidemiology and Genetics, 2010, 1, 193-200.	0.4	12
223	Rs5848 Variant Influences GRN mRNA Levels in Brain and Peripheral Mononuclear Cells in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 18, 603-612.	1.2	59
224	Tetracyclines and Prion Infectivity. Infectious Disorders - Drug Targets, 2009, 9, 23-30.	0.4	48
225	The Serotonin Transporter Promoter Polymorphic Region is not a Risk Factor for Alzheimer's Disease Related Behavioral Disturbances. Journal of Alzheimer's Disease, 2009, 18, 125-130.	1.2	13
226	Epistasis between IL1A, IL1B, TNF, HTR2A, 5-HTTLPR and TPH2 Variations Does Not Impact Alcohol Dependence Disorder Features. International Journal of Environmental Research and Public Health, 2009, 6, 1980-1990.	1.2	10
227	Serotonin Transporter Gene Polymorphic Element <i>5-HTTLPR</i> Increases the Risk of Sporadic Parkinson's Disease in Italy. European Neurology, 2009, 62, 120-123.	0.6	15
228	JNK regulates APP cleavage and degradation in a model of Alzheimer's disease. Neurobiology of Disease, 2009, 33, 518-525.	2.1	134
229	ST1859 reduces prion infectivity and increase survival in experimental scrapie. Archives of Virology, 2009, 154, 1539-1544.	0.9	2
230	Interleukin-6 plasma level increases with age in an Italian elderly population ("The Treviso) Tj ETQq0 0 0 rgBT 155-162.	Overlock 3.0	10 Tf 50 227 28
231	A polymorphic variant of the insulin-like growth factor 1 (IGF-1) receptor correlates with male longevity in the Italian population: a genetic study and evaluation of circulating IGF-1 from the "Treviso Longeva (TRELONG)" study. BMC Geriatrics, 2009, 9, 19.	1.1	28
232	The SIRT1 activator resveratrol protects SKâ€Nâ€BE cells from oxidative stress and against toxicity caused by αâ€synuclein or amyloidâ€Î² (1â€42) peptide. Journal of Neurochemistry, 2009, 110, 1445-1456.	2.1	241
233	TPH2 gene variants and anxiety during alcohol detoxification outcome. Psychiatry Research, 2009, 167, 106-114.	1.7	10
234	Lack of Association between Interleukin-1 alpha rs1800587 Polymorphism and Alzheimer's Disease in Two Independent European Samples. Journal of Alzheimer's Disease, 2009, 16, 181-187.	1.2	24

#	Article	IF	CITATIONS
235	Multidisciplinary Perspectives for Alzheimer's and Parkinson's Diseases: Hydrogels for Protein Delivery and Cell-Based Drug Delivery as Therapeutic Strategies. International Journal of Artificial Organs, 2009, 32, 836-850.	0.7	48
236	The anti-fibrillogenic activity of tetracyclines on PrP 106–126: a 3D-QSAR study. Journal of Molecular Modeling, 2008, 14, 987-994.	0.8	20
237	Association study to evaluate the serotonin transporter and apolipoprotein E genes in frontotemporal lobar degeneration in Italy. Journal of Human Genetics, 2008, 53, 1029-1033.	1.1	8
238	Conformational Plasticity of the Gerstmann–StrÃ ¤ ssler–Scheinker Disease Peptide as Indicated by Its Multiple Aggregation Pathways. Journal of Molecular Biology, 2008, 381, 1349-1361.	2.0	56
239	Role of VEGF gene variability in longevity: A lesson from the Italian population. Neurobiology of Aging, 2008, 29, 1917-1922.	1.5	12
240	Mutant Prion Protein Expression Causes Motor and Memory Deficits and Abnormal Sleep Patterns in a Transgenic Mouse Model. Neuron, 2008, 60, 598-609.	3.8	97
241	Early-Onset Alzheimer Disease in an Italian Family With Presenilin-1 Double Mutation E318G and G394V. Alzheimer Disease and Associated Disorders, 2008, 22, 184-187.	0.6	15
242	DJ-1 Modulates α-Synuclein Aggregation State in a Cellular Model of Oxidative Stress: Relevance for Parkinson's Disease and Involvement of HSP70. PLoS ONE, 2008, 3, e1884.	1.1	116
243	The Efficacy of Tetracyclines in Peripheral and Intracerebral Prion Infection. PLoS ONE, 2008, 3, e1888.	1.1	94
244	Neurotoxic and Gliotrophic Activity of a Synthetic Peptide Homologous to Gerstmann-Straussler-Scheinker Disease Amyloid Protein. Journal of Neuroscience, 2007, 27, 1576-1583.	1.7	35
245	JNK Signalling: A Possible Target to Prevent Neurodegeneration. Current Pharmaceutical Design, 2007, 13, 1875-1886.	0.9	218
246	Presenilin-1 mutation E318G and familial Alzheimer's disease in the Italian population. Neurobiology of Aging, 2007, 28, 1682-1688.	1.5	21
247	Time-course of c-Jun N-terminal kinase activation after cerebral ischemia and effect of D-JNKI1 on c-Jun and caspase-3 activation. Neuroscience, 2007, 150, 40-49.	1.1	79
248	Absence of TREM2 polymorphisms in patients with Alzheimer's disease and Frontotemporal Lobar Degeneration. Neuroscience Letters, 2007, 411, 133-137.	1.0	18
249	A novel PSENEN mutation in a patient with complaints of memory loss and a family history of dementia. , 2007, 3, 235-238.		8
250	The Treviso Longeva (Trelong) study: A biomedical, demographic, economic and social investigation on people 70 years and over in a typical town of North-East of Italy. Archives of Gerontology and Geriatrics, 2007, 44, 173-192.	1.4	22
251	Associations of the plasma interleukin 6 (IL-6) levels with disability and mortality in the elderly in the Treviso Longeva (Trelong) study. Archives of Gerontology and Geriatrics, 2007, 44, 193-198.	1.4	15
252	The TAT-JNK inhibitor peptide interferes with beta amyloid protein stability. Cell Death and Differentiation, 2007, 14, 1845-1848.	5.0	39

#	Article	IF	CITATIONS
253	The urokinase-type plasminogen activator polymorphism PLAU_1 is a risk factor for APOE-ε4 non-carriers in the Italian Alzheimer's disease population and does not affect the plasma Aβ(1–42) level. Neurobiology of Disease, 2007, 25, 609-613.	2.1	9
254	Prion Diseases. CNS Drugs, 2006, 20, 15-28.	2.7	26
255	Aggregation/Fibrillogenesis of Recombinant Human Prion Protein and Gerstmannâ``Strässlerâ^`Scheinker Disease Peptides in the Presence of Metal Ions. Biochemistry, 2006, 45, 6724-6732.	1.2	38
256	Candidate gene analysis of IP-10 gene in patients with Alzheimer's disease. Neuroscience Letters, 2006, 404, 217-221.	1.0	17
257	Interleukin-1 alpha and beta, TNF-alpha and HTTLPR gene variants study on alcohol toxicity and detoxification outcome. Neuroscience Letters, 2006, 406, 107-112.	1.0	10
258	Plasma levels of beta-amyloid (1–42) in Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging, 2006, 27, 904-905.	1.5	97
259	Analysis of the cerebellar proteome in a transgenic mouse model of inherited prion disease reveals preclinical alteration of calcineurin activity. Proteomics, 2006, 6, 2823-2834.	1.3	19
260	A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease. Clinical Pharmacology and Therapeutics, 2006, 80, 216-227.	2.3	53
261	Glomerular podocytes contain neuronâ€like functional synaptic vesicles. FASEB Journal, 2006, 20, 976-978.	0.2	100
262	Identification of prion protein gene polymorphisms in goats from Italian scrapie outbreaks. Journal of General Virology, 2006, 87, 1029-1033.	1.3	95
263	Gerstmann-StrÃ ¤ ssler-Scheinker Disease Amyloid Protein Polymerizes According to the "Dock-and-Lock―Model. Journal of Biological Chemistry, 2006, 281, 843-849.	1.6	33
264	Association of neuronal nitric oxide synthase C276T polymorphism with Alzheimer's disease. Journal of Neurology, 2005, 252, 985-986.	1.8	17
265	PEN–2 gene mutation in a familial Alzheimer's disease case. Journal of Neurology, 2005, 252, 1033-1036.	1.8	27
266	Role of Plasminogen in Propagation of Scrapie. Journal of Virology, 2005, 79, 11225-11230.	1.5	18
267	Cytosolic Prion Protein (PrP) Is Not Toxic in N2a Cells and Primary Neurons Expressing Pathogenic PrP Mutations. Journal of Biological Chemistry, 2005, 280, 11320-11328.	1.6	104
268	Genotype-Dependent Activity of Tryptophan Hydroxylase-2 Determines the Response to Citalopram in a Mouse Model of Depression. Journal of Neuroscience, 2005, 25, 8165-8172.	1.7	131
269	Rat nicastrin gene: cDNA isolation, mRNA variants and expression pattern analysis. Molecular Brain Research, 2005, 136, 12-22.	2.5	14
270	The T-786C NOS3 polymorphism in Alzheimer's disease: Association and influence on gene expression. Neuroscience Letters, 2005, 382, 300-303.	1.0	26

#	Article	IF	CITATIONS
271	The neurotoxicity of prion protein (PrP) peptide 106–126 is independent of the expression level of PrP and is not mediated by abnormal PrP species. Molecular and Cellular Neurosciences, 2005, 28, 165-176.	1.0	55
272	Influence of the Glu298Asp polymorphism of NOS3 on age at onset and homocysteine levels in AD patients. Neurobiology of Aging, 2005, 26, 789-794.	1.5	36
273	Hereditary Prion Protein Amyloidoses. , 2005, , 83-109.		1
274	Protective effect of TATâ€delivered αâ€synuclein: relevance of the Câ€ŧerminal domain and involvement of HSP70. FASEB Journal, 2004, 18, 1713-1715.	0.2	77
275	P3-357 Structural properties of gerstmann-StrÃ ¤ ssler-Scheinker disease amyloid protein. Neurobiology of Aging, 2004, 25, S457.	1.5	0
276	P4-415 ST1859 reduces prion infectivity and increase survival in experimental scrapie. Neurobiology of Aging, 2004, 25, S592.	1.5	0
277	The contribution of the immune system to prion diseases. Drug Discovery Today Disease Mechanisms, 2004, 1, 351-356.	0.8	3
278	CCR2-64I polymorphism and CCR5î"32 deletion in patients with Alzheimer's disease. Journal of the Neurological Sciences, 2004, 225, 79-83.	0.3	35
279	MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. Neurobiology of Aging, 2004, 25, 1169-1173.	1.5	77
280	Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. American Journal of Clinical Nutrition, 2004, 80, 114-22.	2.2	258
281	Cytotoxicity of PrP Peptides. , 2004, , 176-197.		1
282	Quinacrine blocks PrP (106-126)-formed channels. Journal of Neuroscience Research, 2003, 74, 934-941.	1.3	21
283	Proteasome inhibition and aggregation in Parkinson's disease: a comparative study in untransfected and transfected cells. Journal of Neurochemistry, 2003, 88, 545-553.	2.1	67
284	Therapeutic approaches to prion diseases. Clinics in Laboratory Medicine, 2003, 23, 187-208.	0.7	14
285	Nicastrin gene in familial and sporadic Alzheimer's disease. Neuroscience Letters, 2003, 353, 61-65.	1.0	14
286	Tumor necrosis factor \hat{I}_{\pm} polymorphism C-850T is not associated with Alzheimer's disease and vascular dementia in an Italian population. Neuroscience Letters, 2003, 344, 135-137.	1.0	26
287	Effect of β-amyloid on endothelial cells: lack of direct toxicity, enhancement of MTT-induced cell death and intracellular accumulation. Neurochemistry International, 2003, 43, 251-261.	1.9	23
288	Nicastrin gene in familial and sporadic Alzheimer's disease. Neuroscience Letters, 2003, 353, 61-61.	1.0	1

#	Article	IF	CITATIONS
289	Evaluation of Quinacrine Treatment for Prion Diseases. Journal of Virology, 2003, 77, 8462-8469.	1.5	190
290	Structural Properties of Gerstmann-StrÃ ¤ ssler-Scheinker Disease Amyloid Protein. Journal of Biological Chemistry, 2003, 278, 48146-48153.	1.6	75
291	Molecular analysis of iatrogenic scrapie in Italy. Journal of General Virology, 2003, 84, 1047-1052.	1.3	15
292	Pure spastic paraparesis associated with a novel presenilin 1 R278K mutation. Neurology, 2003, 60, 150-150.	1.5	35
293	Channels formed with a mutant prion protein PrP(82-146) homologous to a 7-kDa fragment in diseased brain of GSS patients. American Journal of Physiology - Cell Physiology, 2003, 285, C862-C872.	2.1	53
294	Prion Diseases: Time for a Therapy ?. Current Medicinal Chemistry Immunology, Endocrine & Metabolic Agents, 2003, 3, 185-197.	0.2	10
295	Tetracyclines affect prion infectivity. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10849-10854.	3.3	184
296	Synthetic Miniprion PrP106. Journal of Biological Chemistry, 2002, 277, 31327-31334.	1.6	32
297	Anti-amyloidogenic effect of tetracyclines in Prion and Alzheimer disease models. European Neuropsychopharmacology, 2002, 12, 91.	0.3	1
298	Protein misfolding in Alzheimer's and Parkinson's disease: genetics and molecular mechanisms. Neurobiology of Aging, 2002, 23, 957-976.	1.5	124
299	Neuroprotective Effect of Somatostatin on Nonapoptotic NMDA-Induced Neuronal Death: Role of Cyclic GMP. Journal of Neurochemistry, 2002, 68, 319-327.	2.1	49
300	Prion Protein Fragment 106-126 Differentially Induces Heme Oxygenase-1 mRNA in Cultured Neurons and Astroglial Cells. Journal of Neurochemistry, 2002, 68, 715-720.	2.1	30
301	Amidation of β-Amyloid Peptide Strongly Reduced the Amyloidogenic Activity Without Alteration of the Neurotoxicity. Journal of Neurochemistry, 2002, 69, 2048-2054.	2.1	34
302	Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Letters, 2001, 487, 404-407.	1.3	205
303	Studies on peptide fragments of prion proteins. Advances in Protein Chemistry, 2001, 57, 171-201.	4.4	42
304	Evidence for the transmission of scrapie to sheep and goats from a vaccine against <i>Mycoplasma agalactiae</i> . Veterinary Record, 2001, 148, 531-536.	0.2	38
305	New mutation (R42P) of the parkin gene in the ubiquitinlike domain associated with parkinsonism. Neurology, 2001, 56, 463-466.	1.5	55
306	Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. Biochemical Journal, 2000, 348, 307.	1.7	38

#	Article	IF	CITATIONS
307	Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. Biochemical Journal, 2000, 348, 307-313.	1.7	94
308	Apolipoprotein E and Intronic Polymorphism of Presenilin 1 and Alpha-1-Antichymotrypsin in Alzheimer's Disease and Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 2000, 11, 239-244.	0.7	26
309	?-Synuclein and Parkinson's disease: Selective neurodegenerative effect of ?-synuclein fragment on dopaminergic neurons in vitro and in vivo. Annals of Neurology, 2000, 47, 632-640.	2.8	79
310	Tetracycline affects abnormal properties of synthetic PrP peptides and PrPSc in vitro11Edited by J. Karn. Journal of Molecular Biology, 2000, 300, 1309-1322.	2.0	155
311	Apoptotic Cell Death and Impairment of L-Type Voltage-Sensitive Calcium Channel Activity in Rat Cerebellar Granule Cells Treated with the Prion Protein Fragment 106–126. Neurobiology of Disease, 2000, 7, 299-309.	2.1	64
312	Calcitonin gene-related peptide receptor expression in the neurons and glia of developing rat cerebellum: an autoradiographic and immunohistochemical analysis. Neuroscience, 2000, 100, 381-391.	1.1	33
313	Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neuroscience Letters, 2000, 287, 65-67.	1.0	344
314	Caspase-3 activation by \hat{l}^2 -amyloid and prion protein peptides is independent from their neurotoxic effect. Neuroscience Letters, 2000, 293, 207-210.	1.0	31
315	Intracellular mechanisms mediating the neuronal death and astrogliosis induced by the prion protein fragment 106–126. International Journal of Developmental Neuroscience, 2000, 18, 481-492.	0.7	56
316	Comment on: Neurotoxicity of prion peptide 106-126 not confirmed, by Beat Kunz, Erika Sandmeier, Philipp Christen. FEBS Letters, 2000, 466, 205-206.	1.3	7
317	α-Synuclein and Parkinson's disease: Selective neurodegenerative effect of α-synuclein fragment on dopaminergic neurons in vitro and in vivo. , 2000, 47, 632.		6
318	Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. Biochemical Journal, 2000, 348 Pt 2, 307-13.	1.7	31
319	Alpha-synuclein and Parkinson's disease: selective neurodegenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo. Annals of Neurology, 2000, 47, 632-40.	2.8	13
320	Determination of solution conformations of PrP106-126, a neurotoxic fragment of prion protein, by1H NMR and restrained molecular dynamics. FEBS Journal, 1999, 266, 1192-1201.	0.2	32
321	Influence of mutations associated with familial prion-related encephalopathies on biological activity of prion protein peptides. Annals of Neurology, 1999, 45, 489-494.	2.8	20
322	Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106‒126. Biochemical Journal, 1999, 342, 207.	1.7	36
323	Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106–126. Biochemical Journal, 1999, 342, 207-214.	1.7	100
324	Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106-126. Biochemical Journal, 1999, 342 (Pt 1), 207-14.	1.7	21

#	Article	IF	CITATIONS
325	Prion protein fragment 106-126 induces apoptotic cell death and impairment of L-type voltage-sensitive calcium channel activity in the GH3 cell line. , 1998, 54, 341-352.		73
326	Somatostatin expression in TS16 mouse brain cultures. Journal of Molecular Neuroscience, 1998, 10, 99-111.	1.1	2
327	Extracellular Calcium Deprivation in Astrocytes: Regulation of mRNA Expression and Apoptosis. Journal of Neurochemistry, 1998, 70, 1474-1483.	2.1	42
328	PrP Peptides as a Tool to Investigate the Pathogenesis of Prion Protein Amyloidoses. , 1998, , 285-289.		0
329	Interferon-Î ³ Potentiates Interleukin (IL)-6 and Tumor Necrosis Factor-α But Not IL-1Î ² Induced by Endotoxin in the Brain. Endocrinology, 1997, 138, 5220-5226.	1.4	28
330	ANTHRACYCLINES EFFECTIVE AGAINST EXPERIMENTAL SCRAPIE. Journal of Neuropathology and Experimental Neurology, 1997, 56, 595.	0.9	0
331	Effectiveness of Anthracycline Against Experimental Prion Disease in Syrian Hamsters. Science, 1997, 276, 1119-1121.	6.0	168
332	Î ² -AMYLOID FRAGMENT POTENTIATES IL-6 AND TNF-Î \pm SECRETION BY LPS IN ASTROCYTES BUT NOT IN MICROGLI Cytokine, 1997, 9, 759-762.	A _{1.4}	81
333	Densitometric Quantification of Neuronal Viability by Computerized Image Analysis. Experimental Neurology, 1997, 148, 281-287.	2.0	16
334	A Neurotoxic and Gliotrophic Fragment of the Prion Protein Increases Plasma Membrane Microviscosity. Neurobiology of Disease, 1997, 4, 47-57.	2.1	60
335	Influence of cell culture conditions on the protective effect of antioxidants against β-amyloid toxicity: studies with lazaroids. Brain Research, 1997, 764, 293-298.	1.1	19
336	Oxidative stress after acute and chronic application of β-amyloid fragment 25–35 in cortical cultures. Neuroscience Letters, 1996, 203, 61-65.	1.0	38
337	Amyloid in alzheimer's disease and prion-related encephalopathies: Studies with synthetic peptides. Progress in Neurobiology, 1996, 49, 287-315.	2.8	54
338	Intracellular Calcium Rise through L-Type Calcium Channels, as Molecular Mechanism for Prion Protein Fragment 106-126-Induced Astroglial Proliferation. Biochemical and Biophysical Research Communications, 1996, 228, 397-405.	1.0	76
339	Neurotoxicity of Î ² -amyloid and prion peptides. Current Opinion in Neurology, 1996, 9, 492.	1.8	48
340	Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes. Biochemical Journal, 1996, 320, 563-570.	1.7	49
341	Apoptosis-mediated neurotoxicity induced by β-amyloid and PRP fragments. Molecular and Chemical Neuropathology, 1996, 28, 163-171.	1.0	90
342	Clusterin (SGP-2) Induction in Rat Astroglial Cells Exposed to Prion Protein Fragment 106-126. European Journal of Neuroscience, 1996, 8, 589-597.	1.2	37

#	Article	IF	CITATIONS
343	β25–35 Alters Calcium Homeostasis and Induces Neurotoxicity in Cerebellar Granule Cells. Journal of Neurochemistry, 1996, 66, 1995-2003.	2.1	38
344	A PRION PROTEIN FRAGMENT MODIFIES PLASMA MEMBRANE VISCOSITY AND INTRACELLULAR. CALCIUM LEVEL. Journal of Neuropathology and Experimental Neurology, 1995, 54, 449.	0.9	3
345	Gene Expression andIn VitroRelease of Galanin in Rat Hypothalamus During Development. European Journal of Neuroscience, 1995, 7, 944-950.	1.2	10
346	A simple, automatic method for morphometric analysis of the left ventricle in rats with myocardial infarction. Journal of Pharmacological and Toxicological Methods, 1995, 33, 221-229.	0.3	12
347	Central endotoxin induces different patterns of interleukin (IL)-1 beta and IL-6 messenger ribonucleic acid expression and IL-6 secretion in the brain and periphery Endocrinology, 1995, 136, 897-902.	1.4	98
348	Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and Î ² -amyloid production in cultures. Neuroscience Letters, 1995, 188, 70-74.	1.0	195
349	Neuroprotective activity of acetyl-L-carnitine: Studies in vitro. Journal of Neuroscience Research, 1994, 37, 92-96.	1.3	66
350	A Neurotoxic Prion Protein Fragment Induces Rat Astroglial Proliferation and Hypertrophy. European Journal of Neuroscience, 1994, 6, 1415-1422.	1.2	112
351	Nonsteroidal antiinflammatory drug use in Alzheimer's disease. Biological Psychiatry, 1994, 36, 854-856.	0.7	83
352	Neurodegenerative effects induced by β-amyloid and PRP peptides: Similarities and differences. Neurobiology of Aging, 1994, 15, S87.	1.5	0
353	Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein Journal of Biological Chemistry, 1994, 269, 7859-7862.	1.6	173
354	Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. Journal of Biological Chemistry, 1994, 269, 7859-62.	1.6	145
355	In situ hybridization histochemistry quantification: automatic count on single cell in digital image. Journal of Neuroscience Methods, 1993, 47, 93-103.	1.3	19
356	Neurotoxicity of a prion protein fragment. Nature, 1993, 362, 543-546.	13.7	935
357	Quantitative morphology and shape classification of neurons by computerized image analysis. Computer Methods and Programs in Biomedicine, 1993, 41, 89-99.	2.6	31
358	Nerve growth factor does not influence the expression of β amyloid precursor protein mRNA in rat brain: in vivo and in vitro studies. Brain Research, 1993, 620, 292-296.	1.1	26
359	Molecular Characteristics of a Protease-Resistant, Amyloidogenic and Neurotoxic Peptide Homologous to Residues 106-126 of the Prion Protein. Biochemical and Biophysical Research Communications, 1993, 194, 1380-1386.	1.0	212
360	Automatic quantitative evaluation of autoradiographic band films by computerized image analysis. Life Sciences, 1993, 53, PL331-PL336.	2.0	17

#	Article	IF	CITATIONS
361	Mechanical deafferentation of basal forebrain-cortical pathways and neurotoxic lesions of the nucleus basalis magnocellularis: comparative effect on spatial learning and cortical acetylcholine release in vivo. Behavioural Brain Research, 1993, 54, 145-152.	1.2	24
362	Synthetic peptides homologous to prion protein residues 106-147 form amyloid-like fibrils in vitro Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 9678-9682.	3.3	242
363	IN VITRO NEUROTOXICITY OF A FRAGMENT OF THE PRION PROTEIN. Journal of Neuropathology and Experimental Neurology, 1993, 52, 293.	0.9	0
364	Apoptosis mediated neurotoxicity induced by chronic application of β amyloid fragment 25–35. NeuroReport, 1993, 4, 523-526.	0.6	355
365	beta-Amyloid neurotoxicity. Functional Neurology, 1993, 8, 211-25.	1.3	26
366	Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by interleukin-1. Molecular Brain Research, 1992, 16, 128-134.	2.5	251
367	Culture of dorsal root ganglion neurons from aged rats: Effects of acetyl-l-carnitine and NGF. International Journal of Developmental Neuroscience, 1992, 10, 321-329.	0.7	47
368	Expression of GAL mRNA in rat hypothalamus: effect of frontal deafferentation and colchicine treatment. Molecular Brain Research, 1992, 14, 277-281.	2.5	11
369	Chronic infusion of quinolinic acid in rat striatum: effects on discrete neuronal populations. Journal of the Neurological Sciences, 1992, 108, 129-136.	0.3	21
370	Expression of CGRP Binding Sites in the Developing Rat Cerebellum. Annals of the New York Academy of Sciences, 1992, 657, 423-425.	1.8	7
371	Activation of Olivocerebellar Fibers Induces an Increase in CGRP Cerebellar Binding Sites. Annals of the New York Academy of Sciences, 1992, 657, 432-434.	1.8	1
372	Decreased [3H]hemicholinium binding to high-affinity choline uptake sites in aged rat brain. Brain Research, 1992, 570, 354-357.	1.1	17
373	Chemical and pharmacological characterization of galanthamine, an acetylcholinesterase inhibitor, and its derivatives. A potential application in Alzheimer's disease?. European Journal of Medicinal Chemistry, 1992, 27, 673-687.	2.6	94
374	Functional and histological consequences of quinolinic and kainic acid-induced seizures on hippocampal somatostatin neurons. Neuroscience, 1991, 41, 127-135.	1.1	39
375	Modulation of cortical in vivo acetylcholine release by the basal nuclear complex: role of the pontomesencephalic tegmental area. Brain Research, 1991, 563, 353-356.	1.1	40
376	Neurodegenerative Effects Induced by Chronic Infusion of Quinolinic Acid in Rat Striatum and Hippocampus. European Journal of Neuroscience, 1991, 3, 40-46.	1.2	14
377	Longâ€ŧerm acetyl‣â€carnitine treatment in Alzheimer's disease. Neurology, 1991, 41, 1726-1726.	1.5	206
378	Modulation of cerebellar CGRP binding sites induced by climbing fibre activation. NeuroReport, 1990, 1, 215-217.	0.6	5

#	Article	IF	CITATIONS
379	Deprivation of Growth Hormone-Releasing Hormone Early in the Rat's Neonatal Life Permanently Affects Somatotropic Function. Endocrinology, 1990, 127, 1625-1634.	1.4	53
380	Production and characterization of monoclonal antibodies to N-acetyl-aspartyl-glutamate Journal of Histochemistry and Cytochemistry, 1990, 38, 493-502.	1.3	18
381	Increased tryptophan hydroxylase mRNA in raphe serotonergic neurons spared by 5,7-dihydroxytryptamine. Molecular Brain Research, 1990, 8, 343-348.	2.5	43
382	Cholinergic neurons of the pontomesencephalic tegmentum release acetylcholine in the basal nuclear complex of freely moving rats. Neuroscience, 1990, 37, 717-723.	1.1	128
383	Developmental expression of somatostatin in mouse brain. I. Immunocytochemical studies. Developmental Brain Research, 1990, 53, 6-25.	2.1	60
384	Developmental expression of somatostatin in mouse brain. II. In situ hybridization. Developmental Brain Research, 1990, 53, 26-39.	2.1	65
385	Decrease in [3H]hemicholinium binding to high-affinity choline uptake sites in deafferented striatum: restoration by oxiracetam. Brain Research, 1990, 530, 156-160.	1.1	8
386	The postnatal expression of acetylcholinesterase in somatostatin-positive cells of mouse hippocampus. Developmental Brain Research, 1989, 48, 73-85.	2.1	10
387	The effects of N-acetylated alpha-linked acidic dipeptidase (NAALADase) inhibitors on [3H]NAAG catabolism in vivo. Neuroscience Letters, 1989, 100, 295-300.	1.0	48
388	Calcium-Dependent Evoked Release of N[3H]Acetylaspartylglutamate from the Optic Pathway. Journal of Neurochemistry, 1988, 51, 1956-1959.	2.1	67
389	Enhancement of opioid cataleptic response by cortical frontal deafferentation or intrastriatal injection of NMDA-receptor antagonists. Brain Research, 1988, 449, 97-103.	1.1	7
390	Quantitation of N-acetyl-aspartyl-glutamate in microdissected rat brain nuclei and peripheral tissues: findings with a novel liquid phase radioimmunoassay. Molecular Brain Research, 1988, 3, 223-231.	2.5	35
391	Neuroanatomical localization and quantification of amyloid precursor protein mRNA by in situ hybridization in the brains of normal, aneuploid, and lesioned mice Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 3628-3632.	3.3	77
392	Striatal cholinergic function reflects differences in D-2 dopaminergic receptor activation. Life Sciences, 1987, 41, 1717-1723.	2.0	2
393	Co-localization of N-acetyl-aspartyl-glutamate in central cholinergic, noradrenergic, and serotonergic neurons. Synapse, 1987, 1, 455-460.	0.6	97
394	Neurochemical characterization of embryonic brain development in trisomy 19 (Ts19) mice: Implications of selective deficits observed for abnormal neural development in aneuploidy. Genesis, 1987, 8, 267-279.	3.1	18
395	Role of the hippocampus in the sex-dependent regulation of eating behavior: Studies with kainic acid. Physiology and Behavior, 1986, 38, 321-326.	1.0	34
396	Frontal decortication and adaptive changes in striatal cholinergic neurons in the rat. Brain Research, 1986, 363, 128-134.	1.1	27

#	Article	IF	CITATIONS
397	Qualitative differences in the effects of adenosine analogs on the cholinergic systems of rat striatum and hippocampus. Naunyn-Schmiedeberg's Archives of Pharmacology, 1986, 334, 86-91.	1.4	5
398	Regulation of Drugs Affecting Striatal Cholinergic Activity by Corticostriatal Projections. Advances in Behavioral Biology, 1986, , 973-980.	0.2	0
399	Characterization of the alpha adrenergic receptor population in hippocampus up regulated by serotonergic raphe deafferentiation. Life Sciences, 1985, 36, 255-270.	2.0	8
400	Studies on the up regulation of alpha-adrenoceptors on rat hippocampal perikarya by chemical lesion of the median raphe nucleus. Life Sciences, 1985, 37, 449-460.	2.0	9
401	Blockade of the diazepam-induced increase in rat striatal acetylcholine content by the specific benzodiazepine antagonists ethyl-β-carboline-3-carboxylate and Ro 15-1788. Brain Research, 1985, 336, 342-345.	1.1	10
402	Neurochemical effects of minaprine, a novel psychotropic drug, on the central cholinergic system of the rat. Psychopharmacology, 1984, 82, 210-214.	1.5	38
403	In vitro and in vivo evidence for the existence of presynaptic muscarinic cholinergic receptors in the rat hippocampus. Brain Research, 1984, 309, 147-151.	1.1	19
404	Modifications in recognition sites for neurotransmitters in rat hippocampus by kainic acid lesion. Brain Research, 1983, 274, 165-170.	1.1	15
405	Mediation by the corticostriatal input of the in vivo increase in rat striatal acetylcholine content induced by 2-chloroadenosine. Biochemical Pharmacology, 1983, 32, 2993-2996.	2.0	3
406	Modulation of the hippocampal α-adrenoceptor population by lesion of the serotonergic raphe-hippocampal pathway in rats. Life Sciences, 1982, 30, 1113-1119.	2.0	21
407	Studies on the indirect feedback inhibition of cholinergic neurons triggered by oxotremorine in striatum. Brain Research, 1981, 225, 217-223.	1.1	7
408	Evidence for noradrenergic mediation of the oxotremorine-induced increase in acetylcholine content in rat hippocampus. Brain Research, 1980, 187, 494-498.	1.1	19
409	Therapeutic Approaches to Prion Diseases: In Vitro Studies with Tetracycline Compounds. , 0, , 809-820.		1